NO20032581L - Farmasöytisk formulering av gepiron for oral administrering - Google Patents
Farmasöytisk formulering av gepiron for oral administreringInfo
- Publication number
- NO20032581L NO20032581L NO20032581A NO20032581A NO20032581L NO 20032581 L NO20032581 L NO 20032581L NO 20032581 A NO20032581 A NO 20032581A NO 20032581 A NO20032581 A NO 20032581A NO 20032581 L NO20032581 L NO 20032581L
- Authority
- NO
- Norway
- Prior art keywords
- gepirone
- amount
- weight
- oral administration
- certain amount
- Prior art date
Links
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title abstract 5
- 229960000647 gepirone Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 235000010980 cellulose Nutrition 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Denne oppfinnelse tilveiebringer et farmasøytisk preparat for oral administrering, med langvarig frigjøring, omfattende en viss mengde gepironhydroklorid, en viss mengde av en cellulosepolymermatriks og en viss mengde mikrokrystallinsk cellulose, kjennetegnet ved at mengden av den farmasøytisk akseptable cellulosepolymermatriks er fra 70 til 85 vekt%, mengden av karbohydratbindemiddel er fra 7 til 10 vekt% og mengden av gepironhydroklorid er fra 13 til 21 vekt%. Preparatet er anvendelig for behandling av depresjon eller en beslektet sentramervessternforstyrrelse med gepiron administrert i et oralpreparat for tilføring én gang daglig, for langvarig frigjøring av gepiron.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00204388 | 2000-12-08 | ||
| PCT/EP2001/014189 WO2002045753A2 (en) | 2000-12-08 | 2001-11-30 | Oral extended release formulation of gepirone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032581D0 NO20032581D0 (no) | 2003-06-06 |
| NO20032581L true NO20032581L (no) | 2003-06-06 |
Family
ID=8172397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032581A NO20032581L (no) | 2000-12-08 | 2003-06-06 | Farmasöytisk formulering av gepiron for oral administrering |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1343504A2 (no) |
| JP (1) | JP2004517083A (no) |
| KR (1) | KR20040018314A (no) |
| CN (1) | CN1479620A (no) |
| AR (1) | AR031461A1 (no) |
| AU (1) | AU2002226371A1 (no) |
| BR (1) | BR0115976A (no) |
| CA (1) | CA2436692A1 (no) |
| CZ (1) | CZ20031589A3 (no) |
| EC (1) | ECSP034627A (no) |
| HU (1) | HUP0401021A2 (no) |
| IL (1) | IL155855A0 (no) |
| MX (1) | MXPA03005099A (no) |
| NO (1) | NO20032581L (no) |
| PL (1) | PL362445A1 (no) |
| RU (1) | RU2003120446A (no) |
| SK (1) | SK6942003A3 (no) |
| WO (1) | WO2002045753A2 (no) |
| ZA (1) | ZA200303915B (no) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060134193A1 (en) * | 2002-09-24 | 2006-06-22 | Pieter De Haan | Method to improve pharmaceutical tablets having a matrix of cellulose ether |
| WO2006052227A1 (en) * | 2004-11-05 | 2006-05-18 | Fabre-Kramer Holdings, Inc. | High-dosage extended-release formulation of gepirone |
| US20200205456A1 (en) * | 2017-07-26 | 2020-07-02 | Abbott Laboratories | Nutritional tablets and methods of making the same |
| CN109745323A (zh) * | 2017-11-01 | 2019-05-14 | 四川科瑞德制药股份有限公司 | 氮哌酮类化合物提高副交感神经活性的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2001
- 2001-11-30 KR KR10-2003-7007555A patent/KR20040018314A/ko not_active Withdrawn
- 2001-11-30 JP JP2002547535A patent/JP2004517083A/ja not_active Withdrawn
- 2001-11-30 HU HU0401021A patent/HUP0401021A2/hu unknown
- 2001-11-30 RU RU2003120446/15A patent/RU2003120446A/ru not_active Application Discontinuation
- 2001-11-30 CA CA002436692A patent/CA2436692A1/en not_active Abandoned
- 2001-11-30 AU AU2002226371A patent/AU2002226371A1/en not_active Abandoned
- 2001-11-30 PL PL01362445A patent/PL362445A1/xx not_active Application Discontinuation
- 2001-11-30 EP EP01995688A patent/EP1343504A2/en not_active Withdrawn
- 2001-11-30 WO PCT/EP2001/014189 patent/WO2002045753A2/en not_active Ceased
- 2001-11-30 BR BR0115976-3A patent/BR0115976A/pt not_active Application Discontinuation
- 2001-11-30 CN CNA018201792A patent/CN1479620A/zh active Pending
- 2001-11-30 MX MXPA03005099A patent/MXPA03005099A/es unknown
- 2001-11-30 IL IL15585501A patent/IL155855A0/xx unknown
- 2001-11-30 SK SK694-2003A patent/SK6942003A3/sk unknown
- 2001-11-30 CZ CZ20031589A patent/CZ20031589A3/cs unknown
- 2001-12-07 AR ARP010105683A patent/AR031461A1/es not_active Application Discontinuation
-
2003
- 2003-05-20 ZA ZA200303915A patent/ZA200303915B/en unknown
- 2003-05-28 EC EC2003004627A patent/ECSP034627A/es unknown
- 2003-06-06 NO NO20032581A patent/NO20032581L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20031589A3 (cs) | 2003-11-12 |
| WO2002045753A3 (en) | 2002-08-29 |
| WO2002045753A2 (en) | 2002-06-13 |
| AU2002226371A1 (en) | 2002-06-18 |
| CN1479620A (zh) | 2004-03-03 |
| NO20032581D0 (no) | 2003-06-06 |
| PL362445A1 (en) | 2004-11-02 |
| SK6942003A3 (en) | 2003-10-07 |
| MXPA03005099A (es) | 2004-02-12 |
| KR20040018314A (ko) | 2004-03-03 |
| RU2003120446A (ru) | 2005-02-20 |
| BR0115976A (pt) | 2003-12-30 |
| ZA200303915B (en) | 2004-08-20 |
| CA2436692A1 (en) | 2002-06-13 |
| EP1343504A2 (en) | 2003-09-17 |
| HUP0401021A2 (hu) | 2004-09-28 |
| AR031461A1 (es) | 2003-09-24 |
| JP2004517083A (ja) | 2004-06-10 |
| ECSP034627A (es) | 2004-09-28 |
| IL155855A0 (en) | 2003-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050481L (no) | Doseringsform av pramipexol for dosering en gang pr. dag | |
| MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| BR0109875A (pt) | Tratamento de doenças respiratórias | |
| MY140576A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
| MX2007000008A (es) | Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol. | |
| BG105857A (en) | Pregelatinized starch in a controlled release formulation | |
| WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| NO20070578L (no) | Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol | |
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| BR9916361A (pt) | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia | |
| DE60120648D1 (de) | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| BR0211198A (pt) | Composições farmacêuticas e seu uso | |
| KR960010007A (ko) | 게피론 용량형 | |
| ES2171440T3 (es) | Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal. | |
| CA2416771A1 (en) | 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders | |
| HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
| AP1485A (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin. | |
| MX2008006037A (es) | Drogas para el sistema nervioso central para administracion una-vez-al-dia. | |
| MY143571A (en) | Eplerenone crystalline form | |
| DE69803670D1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
| ITMI20080798A1 (it) | Composizione a rilascio modificato a base di doxofillina | |
| AR031461A1 (es) | FORMULACION FARMACEUTICA PARA ADMINISTRACION ORAL CON PROPIEDADES DE LIBERACION PROLONGADA, QUE COMPRENDE GEPIRONA CLORHIDRATO, UNA MATRIZ DE POLíMERO CELULoSICO Y UNA CELULOSA MICROCRISTALINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |